Sandip Kapadia Biography and Net Worth

Chief Financial Officer and Chief Administrative Officer of Harmony Biosciences

Mr. Kapadia is Chief Financial Officer and Chief Administrative Officer. He has over 25 years of life sciences industry experience across multiple therapeutic areas and has provided strategic financial oversight and guidance to companies both in the United States and Europe. Most recently, Mr. Kapadia served as Chief Financial Officer at Intercept Pharmaceuticals, Inc., a biopharmaceutical company, from July 2016 to March 2021 where he built upon the company’s key functional capabilities, developed, and executed financial and capital strategies to prepare for commercial launch. Prior to joining Intercept, Mr. Kapadia served in various financial leadership capacities over 19 years at Novartis International AG and Novartis affiliates in the United States, Switzerland, the Netherlands, and the United Kingdom. He also serves as a director of Molecular Partners AG, Passage Bio, and Alentis Therapeutics. Mr. Kapadia received a Master of Business Administration (MBA) from Rutgers Graduate School of Management and a bachelor’s degree from Montclair State University and is also a US Certified Public Accountant.

What is Sandip Kapadia's net worth?: The estimated net worth of Sandip Kapadia is at least $803.80 thousand as of January 26th, 2026. Mr. Kapadia owns 24,521 shares of Harmony Biosciences stock worth more than $803,798 as of May 7th. This net worth approximation does not reflect any other investments that Mr. Kapadia may own. Learn More about Sandip Kapadia's net worth.
How do I contact Sandip Kapadia?: The corporate mailing address for Mr. Kapadia and other Harmony Biosciences executives is 630 W GERMANTOWN PIKE SUITE 215, PLYMOUTH MEETING PA, 19462. Harmony Biosciences can also be reached via phone at 484-539-9800 and via email at [email protected]. Learn More on Sandip Kapadia's contact information.
Has Sandip Kapadia been buying or selling shares of Harmony Biosciences?: Sandip Kapadia has not been actively trading shares of Harmony Biosciences within the last three months. Most recently, Sandip Kapadia sold 3,746 shares of the business's stock in a transaction on Monday, January 26th. The shares were sold at an average price of $37.15, for a transaction totalling $139,163.90. Following the completion of the sale, the chief financial officer now directly owns 24,521 shares of the company's stock, valued at $910,955.15. Learn More on Sandip Kapadia's trading history.
Who are Harmony Biosciences' active insiders?: Harmony Biosciences' insider roster includes Jeffrey Dayno (Insider), Jeffrey Dierks (Insider), John Jacobs (CEO), Sandip Kapadia (Chief Financial Officer and Chief Administrative Officer), and Andreas Wicki (Director). Learn More on Harmony Biosciences' active insiders.
Are insiders buying or selling shares of Harmony Biosciences?: In the last year, insiders at the sold shares 3 times. They sold a total of 50,640 shares worth more than $1,932,255.65. The most recent insider tranaction occured on January, 26th when CFO Sandip Kapadia sold 3,746 shares worth more than $139,163.90. Insiders at Harmony Biosciences own 11.0% of the company. Learn More about insider trades at Harmony Biosciences.
Information on this page was last updated on 1/26/2026.

Sandip Kapadia Insider Trading History at Harmony Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/26/2026	Sell	3,746	$37.15	$139,163.90	24,521
1/15/2026	Sell	20,961	$35.92	$752,919.12
1/27/2025	Sell	1,775	$38.05	$67,538.75
1/21/2025	Sell	25,000	$40.18	$1,004,500.00

Sandip Kapadia Buying and Selling Activity at Harmony Biosciences

Harmony Biosciences Company Overview

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Today's Range

Now: $32.78

$32.21

$32.99

50 Day Range

MA: $28.94

$26.54

$32.78

2 Week Range

Now: $32.78

$25.52

$40.87

Volume

748,905 shs

Average Volume

875,011 shs

Market Capitalization

$1.90 billion

P/E Ratio

12.10

Dividend Yield

N/A

Beta

0.97